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Abstract
Background: Nephrotic syndrome is traditionally classified on the basis of the response to standard steroid
treatment. Mutations in more than 24 genes have been associated with nephrotic syndrome in children, although
the great majority of steroid-resistant cases have been attributed to mutations in three main genes: NPHS1, NPHS2
and WT1. The aims of this study were to identify mutations in these genes more frequently reported as mutated
and to characterize each variation using different in silico prediction algorithms in order to understand their
biological functions.
Methods: We performed direct sequence analysis of exons 8 and 9 of WT1, 8 exons of NPHS2 and 29 exons of
NPHS1, including NPHS2 and NPHS1 intron–exon boundary sequences, as well as 700 bp of the 5′ UTR from both
genes in 27 steroid-resistant patients aged between 3 months and 18 years.
Results: Analysis of the NPHS2 gene revealed four missense mutations, one frameshift mutation and three
variations in the 5′ UTR. Four patients presented compound heterozygosis, and four other patients presented one
heterozygous alteration only. WT1 and NPHS1 gene analysis did not reveal any mutations.
Discussion: This is the first study focusing on genetics of SRNS in Brazilian children. Identification of mutations is
important because it could influence physicians’ decision on patient treatment, as patients carrying mutations
can be spared the side effects of immunosuppressive therapy and ultimately could be considered for kidney
transplantation from a living donor.
Conclusions: After molecular analysis of the genes more frequently reported as mutated in 27 steroid-resistant
nephrotic syndrome patients, we identified NPHS2 mutations confirming the hereditary character of the kidney
disease in only 14.8 % of patients. Therefore, the next step is to perform a next generation sequencing based
analysis of glomeluropathy-related panel of genes for the remaining patients in order to search for mutations in
other genes related to steroid-resistant nephrotic syndrome.
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Background
Nephrotic syndrome (NS) is considered as one of the
main kidney diseases in children and is characterized by
proteinuria, edema, hypoalbuminemia and hyperlipid-
emia [1]. Depending on the age at diagnosis, NS is usu-
ally classified as congenital (CNS) when it manifests in
utero or during the first 3 months of life; as infantile
when it occurs during the first year; as childhood when
symptoms occur between 1 and 12 years of age; and as
juvenile with onset between 12 and 18 years of age [2].
Approximately 90 % of patients show a favorable out-
come after steroid treatment of NS and are termed
steroid-sensitive NS (SSNS) patients. Clinically, however,
these SSNS patients are not a homogeneous group, as
some continue to develop frequent relapses (FRNS) or
even follow a steroid-dependent course (SDNS) of the
disease. The remaining 10 % are steroid-resistant NS
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(SRNS) patients who do not respond to steroids or to
any other immunosuppressive therapy; they show most
commonly histopathological findings of focal segmental
glomerulosclerosis (FSGS) and generally progress to
end-stage renal disease [2].
A single-gene cause is responsible for approximately
30 % of SRNS cases, as reported in a recent paper by
Sadowski et al. [3] on the largest international cohort
studied so far for monogenic causes of SRNS. By using
an in-house developed high-throughput approach, the
investigators examined 1783 families and identified mu-
tations in 21 out of 27 genes encoding proteins mainly
expressed in the glomerular filtration barrier (GFB). The
clinical course in affected children differs considerably
with respect to the mode of inheritance, age, renal bi-
opsy results, response to immunosuppressive treatment
and extrarenal manifestations. One of the main genes,
NPHS2 (OMIM *604766), encodes podocin, a member
of the stomatin protein family that is localized at the slit
membrane [4]. In the slit–diaphragm (SD) complex,
podocin interacts with nephrin, a member of the im-
munoglobulin superfamily and the principal protein in
the SD [5]. Podocin mediates the recruitment of nephrin
into specialized microdomains of the cell plasma mem-
brane where, in the so-called “lipid rafts”, both proteins
play essential roles in the maintenance of the glomerular
permeability barrier [6]. Moreover, podocin belongs to a
family comprising more than 1800 proteins conserved
throughout evolution that share approximately 150
amino acid domains similar to mitochondrial protein
prohibitin (PHB). Many of the PHB domain proteins
regulate membrane protein function by binding sterols
and altering their local lipid environment [7]. Huber et
al. [8] demonstrated that podocin binds to cholesterol
and contributes to form a supercomplex of proteins and
lipids that regulate ion channel complexes; the authors
also showed that podocin interacts with the cytoplasmic
tail of nephrin, thus potentiating the effect of nephrin
cellular signaling.
Mutations in the NPHS2 gene were originally de-
scribed in families with autosomal recessive SRNS
(nephrotic syndrome type 2, OMIM #600995) [8] but
later were found to be present also in sporadic cases
[9], occurring in approximately 40 % of familial cases
and 6–17 % of sporadic SRNS cases [9–11]. Familial
and sporadic cases with compound heterozygous or
homozygous mutations in NPHS2 typically have disease
onset between 3 months and 5 years of age. Recently,
Bouchireb et al. [12] pointed out that not all ethnic
groups share the same frequency of mutations in this
gene, following an extensive review of NPHS2 muta-
tions in SRNS patients between 1999 and 2013. It was
found that African-American and Asian patients show
a low prevalence of NPHS2 mutations.
Regarding the NPHS1 gene (OMIM *602716) that en-
codes nephrin, two major mutations were originally
identified in Finnish patients with CNS of the Finnish
type (OMIM #256300) [13]. In non-Finnish patients, a
large number of different mutations have been de-
scribed [13–15]. In addition to the typical features of
CNS, mutations in nephrin were also associated with
childhood-onset SRNS in patients aged from 5 months
to 8 years [16]. Furthermore, Koziell et al. [17] described
the coexistence of mutations in NPHS2 and NPHS1 genes
in patients with milder CNS.
A third important gene involved in the genetics of NS
is WT1 (OMIM *607102), which encodes a zinc finger
transcription factor. WT1-dominant mutations were ori-
ginally identified to be responsible for Wilms’ tumor
(WT), a childhood kidney cancer (OMIM #194070)
[18, 19, 20]. WT1 mutations were also associated with
Denys-Drash syndrome (OMIM #194080) [21, 22] and
Frasier syndrome (OMIM #136680) [22]. However,
dominant de novo mutations in exons 8 and 9 have
been found as the cause of approximately 2.7–7 % of
sporadic cases of isolated SRNS in infants and children.
In a recent study, Lipska et al. [23] used the PodoNet
cohort to describe the genotypic and phenotypic spectrum
of WT1-associated kidney disease and found WT1 muta-
tions in 6 % of sporadic SRNS patients, confirming the
prevalence found by previous smaller studies.
Molecular data are clinically relevant to SRNS pa-
tients, because children who do not respond to cortico-
steroids and present with mutations in any of these
genes can be spared the adverse effects of corticoster-
oid treatment. In addition, patients with mutations have
a reduced risk of developing FSGS after renal trans-
plantation, compared to patients without mutations, at
a rate of 8 % versus 30 %, respectively [11].
In our study, we performed sequence analysis of the
entire NPHS2 and NPHS1 genes and exons 8 and 9 of
the WT1 gene in 27 SRNS Brazilian patients, including
seven unrelated familial cases and 20 sporadic cases. We
present nucleotide changes found after screening these
27 SRNS patients.
Methods
Patients
Between 2008 and 2013, 27 SRNS patients, comprising
seven unrelated familial cases and 20 sporadic (isolated)
cases, were included in this study. Prerequisites for en-
rollment included the presence of NS for at least 1 year
and the age at disease onset being between 3 months
and 18 years of age. The median age at disease onset
was 4 years. From the 27 patients, 15 were males and 12
were females. Resistance to steroids was defined by ne-
phrologists who followed up the patients, according to
the International Study of Kidney Disease in Children
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definition [24]. The definition of chronic kidney disease
(CKD) was classified according to the National Kidney
Foundation for patients aged over 2 years [25]. Eight of
27 patients progressed to CKD and had already had a
kidney transplant. Table 1 presents the age at disease on-
set, age at CKD diagnosis and at transplantation, and bi-
opsy and molecular findings. The Ethics Committee
from Faculdade de Ciências Médicas at Universidade
Estadual de Campinas approved this study. Written
informed consent for the study was obtained from all
patients and their parents.
Molecular analysis of NPHS2, NPHS1 and WT1 genes
Genomic DNA was isolated from blood samples using
standard methods [26]. Amplification of all coding
exons, exon–intron boundaries and 700 bp of the 5′
UTR end from both NPHS2 and NPHS1 genes were per-
formed by polymerase chain reaction (PCR). For WT1
gene we performed amplification of exons 8 and 9 only
(for specific primers, see in Additional file 1: Tables S1,
S2 and S3). After PCR reactions and direct sequencing
of products (see Additional file 1), Chromas Pro v.1.5
and CLC Sequence Viewer v.6.6.2, were used to analyze
and compare these sequences with the NPHS2, NPHS1
and WT1 reference sequences in the Ensembl database
(ENSG00000116218, ENSG00000161270, ENSG0000018
4937, respectively; http://www.ensembl.org/index.html).
Bioinformatics analysis
The impact of missense and 5′ UTR variations on podocin
or nephrin structure and function was evaluated using se-
lected bioinformatics tools. SIFT (Sorting Intolerant From
Tolerant; http://sift.jcvi.org/) [27], Polyphen (Polymorph-
ism Phenotyping; http://genetics.bwh.harvard.edu/pph2/)
[28] and Align GVGD (http://agvgd.iarc.fr/agvgd_in-
put.php/) [29] were used to assess potentially damaging
effects of non-synonymous amino acid substitutions (see
in Additional file 1: Table S4). In order to verify conserved
amino acid residues, we performed multiple alignment
analysis using ClustalW program [30] that lines up
orthologs from different species to reveal the identities,
similarities and differences. Human nephrin and podo-
cin sequences were compared with orthologous se-
quences available in UniProt data bank (http://
www.uniprot.org/). Moreover, in order to better under-
stand if missense mutations affected exonic splicing en-
hancers or silencers (ESEs and ESS, respectively)
leading to splicing defects, we further performed predic-
tion analysis using two premRNA splicing prediction
tools: Human Splicing Finder (HSF) [31] and SpliceAid2
[32]. The three 5′ UTR heterozygous alterations were ana-
lyzed using Alibaba2 gene regulation program (http://
www.gene-regulation.com/pub/programs/alibaba2/index.
html) that predicts transcription factor binding sites in the
DNA query using data from TRANSFAC® Public eukaryotic
transcription factors [33].
Table 1 Clinical data of SRNS patients with NPHS2 and NPHS1 alterations
Patient
number
Gender Sporadic/
familiala
Age at
onset (years)
Renal
Biopsyb
Age of onset
to CKD - V
(Yes/No)c
Age of
transplant
(Yes/No)
NPHS2
Nucleotide change Effect on
coding
Ref.
(years) (years)
Steroid Resistant cases with two NPHS2 heterozygous alterations
P6 F spo 12 FSGS Yes/15 Yes/15 c.686G > A p.Arg229Gln [37]
c.851C > T p.Ala284Val [10]
P67 F spo 2.2 DMP No No c.686G > A p.Arg229Gln [37]
c.928G > A p.Glu310Lys [38]
P103 F fam 1.2 FSGS No No c.714delG p.Lis239Argfs*13 ps
c.779 T > A p.Val260Glu [12]
P154 M fam 13 FSGS No No c.686G > A p.Arg229Gln [37]
c.851C > T p.Ala284Val [10]
Steroid Resistant cases with one NPHS2 heterozygous alteration
P111 F spo 3 FSGS No No c.-164C > T - ps
P68 M spo 4 CO No No c.-196C > G - ps
P85 M spo 6.11 CO Yes/8 Yes c.-537_-531delCTTTTTT - [40]
P72 M fam 16 FSGS Yes/18 Yes/18 c.686G > A p.Arg229Gln [37]
aSpo: sporadic; Fam: familial;bFSGS:focal segmental glomerular sclerosis; DMP: diffuse mesangial proliferation; CO: complex =minimal change disease or diffuse
mesangial proliferation or focal segmental glomerular sclerosis; CKD: cchronic kidney disease; n.a.: not analyzed; nd: not determined
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Results and discussion
Since the discovery that inherited structural defects in
the GFB are responsible for a large proportion of SRNS
cases, major breakthrough studies on the discovery of
genes and their implication in the disease have been
carried out mainly in European and North American
countries [3, 4, 14, 34, 35, 36]. In Brazil, genetic screen-
ing of patients with NS in childhood is still incipient.
This is the first study focusing on genetics of SRNS in Bra-
zilian children. Identification of mutations is important
because it could influence physicians’ decision on patient
treatment, as patients carrying mutations can be spared
the side effects of immunosuppressive therapy and ultim-
ately could be considered for kidney transplantation from
a living donor.
Here we present results for a cohort of 27 SRNS pa-
tients from a public hospital that is a reference center
in the South East region of Brazil where approximately
200 patients with NS are routinely followed up. Of
note, the 27 SRNS patients represented a frequency of
13.5 % (27/200), which is in line with the reported
worldwide frequency of 10–20 % for this form of the
disease [2, 11]. However, the cohort was not representa-
tive of the entire country, since the Brazilian population
consists of about 205 million of highly miscegenated
people with diverse and regional features. However,
there is no other genetic study on NS patients in Brazil
for comparison.
Only four patients (two familial and two sporadic
cases) representing a total of 14.8 % showed two het-
erozygous alterations that confirmed the hereditary
character of their kidney disease. Mutations in WT1
exons 8 and 9 and NPHS1 gene were not found.
NPHS2 analysis, however, showed eight alterations:
four missense mutations, one frameshift mutation and
three variations in the 5’ UTR (Table 1).
Sporadic cases
Among the 20 sporadic cases, the c.686G > A transition
in exon 5 leading to p.Arg229Gln [36] was identified in
association with two different pathogenic missense mu-
tations (Table 1). Patient P6 was compound heterozy-
gous [p.Arg229Gln];[p.Ala284Val], as indicated by the
c.851C > T nucleotide transition [9] observed from NP
Fig. 1 Schematic structure of NPHS2/podocin showing the position of alterations and patient’s heredograms. a Eight exons of NPHS2 gene and
podocin illustration showing electropherograms of the three 5’ UTR variants, four missense mutations and the frameshift mutation in the
corresponding exons/domains identified in five SRNS patients. TM = transmembrane domain; PHB = prohibitin domain. b Sporadic cases P6, P67
(first two boxes on the left) and family cases P103, P154 and P72 pedigrees. Black squares and circles represent patients with kidney disease. Arrow
indicates the index case. Mutations are annotated below the individuals that had their NPHS2 or NPHS1 genes screened. P103 (II1) and her sister
(II2) presented [p.Lys239Argfs*13 (;) p.Val260Glu] association. P154 (II4) and her two brothers (II5 and II6) presented the [p.Arg229Gln (;)
p.Ala284Val] association
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HS2 sequencing. Compound heterozygosis for the two
mutations was demonstrated by the analysis of patient
P6’s father carrying p.Ala284Val and mother carrying
p.Arg229Gln (Fig. 1). Patient P67 was compound hetero-
zygous [p.Arg229Gln];[p.Glu310Lys] which resulted from
c.928G >A transition in exon 8 [37]. Individual mutations
were also inherited from each parent, indicating an auto-
somal recessive inheritance for SRNS in both cases (Fig. 1).
The p.Arg229Gln variant is the most frequently re-
ported non-synonymous NPHS2 variant in Caucasians;
there are reports on its allele frequency showing that it
is more frequent among European descendants than
African descendants in the United States [10, 11, 37].
Tsukaguchi et al. demonstrated that trans-association
of p.Arg229Gln with pathogenic mutations may result
in a less severe phenotype such as late-onset SRNS.
The most commonly associated mutation is p.Ala284-
Val, and notably this combination is predominant
among South American populations from Chile and
Argentina with adult-onset SRNS [37]. Recently, Tory
et al., observed that p.Arg229Gln podocin presented a
subcellular mislocalization only when co-expressed
with podocins carrying amino acid substitutions
encoded on exons 7–8, but not with substitutions
encoded on exons 1–6 [38]. The authors suggested that
disease-associated 3′ mutations exert a dominant-negative
effect on p.Arg229Gln podocin, on the basis of a struc-
tural model of dimerization; heterodimers of p.Ala284Val
podocin with p.Arg229Gln podocin showed an altered
three-dimensional structural arrangement, and the au-
thors therefore proposed this different structure contrib-
uted to the retention of p.Arg229Gln podocin within
cytoplasmic compartments. However, when pathogenic
mutations were associated with wild-type podocin, they
behaved as recessive alleles. In summary, Tory et al. [39]
described a phenomenon in an autosomal recessive dis-
order, in which the pathogenicity of one allele depended
on that of the other allele, and they proposed a pattern of
mutation-dependent recessive inheritance in NPHS2-asso-
ciated SRNS that is beyond Mendel’s laws. Based on these
criteria, the pathogenic association [p.Arg229Gln];
[mutEx7–8] was identified in both patients P6 and P67.
Patient P6 was diagnosed with SRNS when proteinuria
occurred at the age of 12 years, thus characterizing a
late-onset form of the disease. Renal biopsy revealed
FSGS, and the patient progressed to CKD in 3 years
when she had a kidney transplant; after approximately
1 year post-transplant, her renal function has now
returned to normal. In contrast, patient P67 developed
proteinuria at 2 years and 2 months of age, and renal
biopsy demonstrated diffuse mesangial proliferation
(Table 1). The same [p.Arg229Gln];[p.Glu310Lys] asso-
ciation was identified by Machuca et al. [37] in three
patients, but all three presented with FSGS. In silico
evaluation using SpliceAid2 and HSF splicing predic-
tion tools for c.686G > A (p.Arg229Gln), c.851C > T
(p.Ala284Val) and c.928G > A (p.Glu310Lys) gave the
following results: SpliceAid2 prediction indicated that
c.686A did not show significant modifications in spli-
cing motifs; c.851 T did not modify protein-binding
recognition motifs; however, c.928A variant disrupted a
hnRNP A1 protein-binding motif in the mutated se-
quence (Fig. 2). HSF prediction indicated that c.686A
did not show modification in sequence motifs (data not
shown); c.851 T created an exonic ESS site; for c.928A
substitution, there was an ESE site broken after HSF
prediction (Table 2).
Considering compound heterozygosis for the two mu-
tations, the percentage of patients with sporadic SRNS
was 10 % (2/20). This result is in accordance with data
published by others that indicated frequencies for pa-
tients bearing two heterozygous mutations varying from
6 to 17 % among sporadic SRNS cases [9–11].
Moreover, among the sporadic cases, there were also
three cases in which we identified only one heterozygous
alteration, the promoter variants c.-164C > T, c.-196C >G
and c.-537_-531delCTTTTTT in patients P111, P68
and P85, respectively. Di Duca et al. [39], who studied
regulatory elements in the NPHS2 promoter, de-
scribed c.-537_-531delCTTTTTT (rs146791300, MAF =
0.069; http://www.ncbi.nlm.nih.gov/) variant as a “func-
tional polymorphism” that downregulated the gene ex-
pression of podocin by 85 % when transfected in
podocytes. As there are no records of c.-164C > T and
c.-196C > G variants in the database (http://www.en
sembl.org), we screened the 700 bp of the 5′ UTR in
278 control subjects. We identified the c.-196G in hetero-
zygosis in two controls (2/278, <1 %), but neither c.-537_-
531delCTTTTTT nor c.-164 T were found, suggesting a
possible role as disease-causing mutations. Alibaba2 gene
regulation prediction algorithm showed that the C >G
transversion in position c.-196 did not disrupt the SP1
transcription binding site located in this region (data not
shown). However, this was not the case for C > T transi-
tion in −164 position that created a new WT1 tran-
scription factor binding site (Fig. 2). It is well known
that WT1 plays a key role during kidney and genital
development [19, 20]. However, after birth, WT1 ex-
pression persists in the glomerular visceral epithelial
cells where the protein probably contributes to the
functional maintenance of differentiated podocytes
[40]. In fact, it was previously demonstrated that WT1
binds and activates a glomerular-specific NPHS1 en-
hancer in vitro [41]. Although there are no reports of
WT1 acting as a trans-regulator element of the NPHS2
promoter, we cannot discard a possible role for WT1 in
this process, since mechanisms by which transcription
factors regulate the expression of their target genes in
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podocytes are not yet fully understood. Recently, He et
al. [42] identified a putative enhancer at 743 bp in the
human NPHS2 promoter that is combinatorially regu-
lated by Lmx1b and FoxC transcription factors in podo-
cytes. Therefore, with respect to c.-164C > T identified
in our study, further expression and electrophoretic
mobility shift assays are essential to better understand
its role in podocin production. What is already known
is that, in proteinuric renal disease, podocin expression
is a dynamic process in which dramatic decreases or
abnormal distributions of podocin expression in glom-
eruli of children with NS have already been demon-
strated [43].
Familial cases
When considering only familial cases, two out of seven
unrelated cases presented two heterozygous alterations.
The new frameshift p.Lys239Argfs*13 was identified in
association with the already described p.Val260Glu mis-
sense in patient P103 and her sister (Fig. 1). We consid-
ered compound heterozygosis as the most probable
genotype characterizing an autosomal recessive inherit-
ance in this family, although we could not analyze their
parent’s NPHS2 gene. The frameshift p.Lys239Argfs*13
results from the c.714delG deletion in exon 5, and puta-
tively produces amino acid changes from residues 239 to
251 and creates a premature stop codon at residue 252.
Fig. 2 Splice Aid2 and Alibaba2 gene regulation in silico predictions. a Splice Aid2 graphic outcomes from c.928G > A (p.Glu310Lys) and c.779 T >
A, (p.Val260Glu) substituions. Top: For c.928G > A the ESS recognition site for hnRNP A1 is broken after G > A substituion. Below: after c.779 T > A
substitution (right) the histogram result shows that, besides the two hnRNPs (H1 and H2) proteins that putatively binds the normal ESS
recognition site, a new motif is created, with the potential of being recognized by the hnRNP A1 and by other four SR proteins. Arrows on the
left of histograms indicate proteins that bind ESEs and ESSs, respectively. The bars have variable width and height respectively related to
the number of nucleotides of the binding site and to its score (binding affinity). Next to each bar there is the label showing the name of the
protein predicted to bind to the recognition motif. Below the histogram there are two lines: one with red bars, representing the recognition
motifs and with a bracket representing a putative splicing site; the other line represents the DNA sequence analyzed. A green circle highlights
the nucleotide substitution. b Alibaba2 gene regulation prediction analysis showing above: wild c.-164C and mutant c.-164 T sequences
(highlighted). Wild sequence was recognized by putative transcription factors ETF-1 and GLI3 and, after substitution, these sites were abolished
and a new recognition site for putative WT1 transcription factor was created. Below: no change after c.-196C > G substitution
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Therefore, this mutation might affect podocin inter-
action with nephrin via the PHB domain, since podocin
PHB domain comprises amino acids 127 to 284 [44].
The missense p.Val260Glu is the result of c.779 T > A
transversion in exon 6 [11]. The protein resulting from
this substitution is retained in the endoplasmic
reticulum and loses its ability to recruit nephrin in lipid
rafts [45]. After in silico evaluation of c.779 T > A
(p.Val260Glu) by HSF and SpliceAid2 splicing predic-
tion tools, this substitution was classified with the po-
tential of interfering with splicing in different ways: by
activating a new exonic cryptic acceptor splice site, as
predicted by HSF matrices; and by creating an ESS site,
as predicted by exonic regulatory sequences (ESRs) al-
gorithm [46] as well as HSF matrices (Table 2). Spli-
ceAid2 prediction indicated that, after T > A substitution,
new ESE and ESS putative binding motifs were created
that might be recognized by different serine and arginine-
rich (SR) proteins and heterogeneous nuclear ribonucleo-
proteins (hnRNP), respectively (Fig. 2). In patient P154,
we also identified the [p.Arg229Gln (;) p.Ala284Val] asso-
ciation, as described for patient P6. Patient P154 is a
13-year-old boy with FSGS. He has five siblings, and we an-
alyzed the NPHS2 gene in two of the siblings, a sister and a
brother with FSGS who also presented the [p.Arg229Gln (;)
p.Ala284Val] association. Analysis of the mother revealed
p.Arg229Gln; however, a DNA sample from the father
was not available for analysis. Our findings also in-
cluded an SRNS patient with only one heterozygous al-
teration in the NPHS2 gene, which diverged from the
concept that SRNS is an autosomal recessive disease.
The p.Arg229Gln substitution was identified in patient
P72 whose father also showed the disease-associated
polymorphism. Patient P72 had the disease onset at
16 years of age when he was diagnosed with FSGS upon
renal biopsy. He progressed to CKD and had kidney
transplant at the age of 18 years. His father was
diagnosed with FSGS and had kidney transplant about
30 years ago, with no FSGS recurrence thereafter. The
family also reported that the patient’s brother died of
renal failure. Therefore, this family history suggests a
possible genetic origin for the disease. Since NPHS2
mutations are expected to act in a recessive mode in
SRNS patients, our hypothesis is that mutations in
other genes might be contributing to the disease in this
family. NPHS1 analysis revealed the c.1223G > A substi-
tution in exon 10, leading to the p.Arg408Gln variant
[14] (Fig. 1). There is some evidence, however, that this
non-synonymous substitution is probably neutral, since
it has been described as a polymorphism frequently
found in homozygosis and heterozygosis in control in-
dividuals [15, 47]. In order to verify its frequency
among Brazilians, we analyzed 100 controls and found
2 % were heterozygous for this variant (data not
shown). In addition, patient P72’s father did not show
this NPHS1 variant, which led to the conclusion that
there might be a mutation in one of the many other
genes implicated in NS that were not screened in the
present work. Besides these three cases with mutations,
the other four cases with a family history of SRNS did
not show any mutations in the NPHS2 gene. Therefore,
the percentage of familial cases carrying two NPHS2
mutations in our study was 28.57 % (2/7), whereas
other groups reported percentages of around 40 % [9–11].
It is likely the small study sample size here could explain
this difference in our frequency result.
Furthermore, we also found that, among four patients
bearing two heterozygous mutations, two (2/4, 50 %)
presented the [p.Arg229Gln];[p.Ala284Val] association
already described as predominant in South American
populations [37]; apparently, this is also a common as-
sociation in South Eastern Brazil. Patient P6’s grandpar-
ents are from Brazil, and the patient herself does not
have a “hispanic” background. She was the only patient
Table 2 Exonic mutations in silico prediction
Enhancer motifs analysis through ESE finder matrices for SRp40, SC35, SF2/ASF and SRp55 proteins
Sequence Variant Sequence positiona Linked SRb protein Reference motif Linked SRb protein Mutant motif Variation
(value 0–100)c (value 0–100)c
c.779 T > A 776 - - SF2/ASF AAGAGGA (80.37) New ESS site
c.851C > T 845 - - SF2/ASF CTGAAGT (75.38) New ESS site
c.928G > A 923 SF2/ASF CAGCTGA (78.10) - - Site broken
Potencial splice sites prediction through HSF matrices
Sequence Variant Sequence position Splice site type Motif New splice site Wild typed Mutantd Variaton
c.779 T > A 769 Acceptor GGAATCAAAGTGGA ggaatcaaagagGA 38.61 67.56 New site +74.98
aPosition in cDNA from ATG codon; bSR = serine/arginine rich proteins; c = Consensus values go from 0 to 100 and the threshold is defined differently for each
algorithm. Threshold for SF2/ASF from ESE finder matrices is 72.98. Every signal with a score above the defined threshold is considered to be a potential ESE/ESS.
dFor HSF matrices consensus values go from 0 to 100 and threshold is 65. Every signal with a score above the threshold is considered to be a splice site (donor or
acceptor). When a mutation occurs if the WT score is under the threshold and the score variation is above +10 % for HSF it is considered that the mutation
creates a new splice site
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who had available information about her grandparents’
origin. The data reported here also demonstrated a
considerable incidence of single heterozygous NPHS2
alterations, but we cannot correlate them with a favor-
able outcome, since two patients (P85 and P72) pro-
gressed to CKD Class V (Table 1). Of note, one of these
two patients presented a promoter variation, and, in
fact, we identified three promoter variations that might
downregulate podocin in the GFB of these patients.
Therefore, further functional studies are necessary, in
order to evaluate if these promoter variants alter the
regulatory mechanisms and influence the maintenance
of the barrier’s functional integrity.
Conclusions
Our study reports the identification of NPHS2 mutations
in only 14.8 % of both sporadic and familial SRNS cases
in the Brazilian patients analyzed, after screening for
mutations in the NPHS2, NPHS1 and WT1 genes. The
study did not reveal mutations in NPHS1 and WT1.
Therefore, target-oriented next generation sequencing
analysis of glomerulopathy-related panel of genes is rec-
ommended to search for mutations in other genes re-
lated to SRNS.
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